Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
300
datasets available to search
ShareScore release 0.9.0
Dataset results
300 results for “infliximab”
Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)
ClinicalTrials.gov study NCT01148901. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
ClinicalTrials.gov study NCT03088293. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
ClinicalTrials.gov study NCT07120152. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
The Effect of Infliximab on Sperm Quality
ClinicalTrials.gov study NCT00745329. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Combination Methotrexate and Infliximab
ClinicalTrials.gov study NCT00432432. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum
ClinicalTrials.gov study NCT03308357. IPD Sharing: NO. Countries: 0. Publications: 0.
Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study
ClinicalTrials.gov study NCT06998797. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study
ClinicalTrials.gov study NCT02683564. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)
ClinicalTrials.gov study NCT00237484. IPD Sharing: YES. Countries: 0. Publications: 0.
"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"
ClinicalTrials.gov study NCT02452151. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Managing Infliximab Reinduction After Temporary Discontinuation of Drug
ClinicalTrials.gov study NCT02771457. IPD Sharing: Not stated. Countries: 0. Publications: 0.
TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Re
ClinicalTrials.gov study NCT02522169. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
ClinicalTrials.gov study NCT04564001. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
ClinicalTrials.gov study NCT01490528. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The relationship between the gene expression profile in the synovium of RA patients at baseline and the clinical response to infliximab treatment
GEO Series GSE21537. Homo sapiens. 62 samples. Type: Expression profiling by array.
Gene expression of CD14- cells from RA, PsA and PsO patients with Infliximab treatment
GEO Series GSE57405. Homo sapiens. 111 samples. Type: Expression profiling by array.
Gene Expression Profiles Predict Infliximab Treatment Response in Patients with Treatment-Resistant Depression
GEO Series GSE45468. Homo sapiens. 216 samples. Type: Expression profiling by array.
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
ClinicalTrials.gov study NCT00443222. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Whole blood gene expression from infliximab treated Crohn's disease patients at three time points: pre-treatment, two weeks and fourteen weeks post first treatment
GEO Series GSE186963. Homo sapiens. 72 samples. Type: Expression profiling by array.
Dataset related to article: "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease"
<p>This record contains raw data related to article "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease"</p> <p>Infliximab (IFX) biosimilars CT-P13 and SB2 have comparable efficacy, safety, and immunogenicity to the originator Remicade (RMC). However, concerns about cross-switching patients between the 3 brands were raised in the absence of cross reactivity data between them. We aimed to determine whether antibodies to infliximab (ATI) in inflammatory bowel disease (IBD) patients cross-react with RMC, CT-P13, and SB2.</p> <p>Methods:</p> <p>Based on previous ATI status, samples from 34 patients participating in the BIOSIM01 study (13 RMC, 9 CT-P13, and 12 switchers) were selected. Patients were treated with either RMC only, or CT-P13 only, or with RMC switched to CT-P13. Additionally, 28 IFX-naïve patients were assayed as controls. In total, 180 samples were analyzed. ATI trough levels were measured in parallel with 3 different bridging Enzyme Linked Immunosorbent Assays constructed using the 3 drugs. Spearman's coefficient and percentages of agreement were used to study the correlation between each assay.</p> <p>Results:</p> <p>In total, 76 samples out of 152 IFX-treated patient samples were ATI-positive (30 RMC, 14 CT-P13, and 32 switchers). All resulted ATI-positive when either CT-P13 or SB2 bridging assays were used. The overall percentage of agreement was 100% when compared either with CT-P13 or SB2 assays. No significant differences were found among ATI levels and coefficients (Spearman's 0.98 to 1.0, P < 0.0001).</p> <p>Conclusions:</p> <p>ATI of RMC-treated, CT-P13-treated or RMC to CT-P13 switched patients show full cross-reactivity with CT-P13 and SB2. Findings suggest that immunodominant epitopes in the reference and CT-P13 drugs are equally present in SB2. Data support full interchangeability between biosimilars in regard to immunogenicity.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.